Relationship between von Willebrand factor activity and therapeutic success of thrombolytic therapy in patients with myocardial infarction

Basit Öğe Kaydı
dc.authorscopusid6507569571
dc.authorscopusid7003978185
dc.authorscopusid7004441048
dc.authorscopusid57215511033
dc.authorscopusid6701686568
dc.contributor.authorKiki, Ilhami
dc.contributor.authorKöse, Nuri
dc.contributor.authorGündo?du, Mehmet
dc.contributor.authorKaya, Hasan
dc.contributor.authorÇetinkaya, Ramazan
dc.date.accessioned2024-09-19T15:48:40Z
dc.date.available2024-09-19T15:48:40Z
dc.date.issued2007
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractAim: Von Willebrand Factor is a glycoprotein, which plays role in primary hemostasis, mainly acts getting platelets to adhere onto the subendothelial tissue and carrying Factor VIII. Although vWF deficient animals had been shown to be resistant to atherosclerosis and thrombotic events, it had not been proven in humans. In this study, we aimed to investigate whether a relationship exists between VWF activity and therapeutic success of thrombolysis. Methods: The study was carried out on 40 patients who were administered thrombolytic therapy due to myocardial infarction and 30 healthy controls. Von Willebrand Factor activity was measured in plasma samples which were taken before the procedure. The results were compared between therapy effective and ineffective patients and controls. Results: Average vWF activity was 131.0±64.0% in patients whereas 113.9±47.7% in controls (p>0.05). On the other hand, mean VWF activities of 24 patients who achieved therapeutic success and 16 therapy failed patients were 103.9±58.9% and 171.7±49.0% respectively (p<0.01). Conclusion: In this study; we found that plasma vWF activity is among the factors affecting the outcome of thrombolytic therapy in patients with myocardial infarction so, it may be used to predict the therapeutic success of thrombolysis.en_US
dc.identifier.doi10.29333/ejgm/82456
dc.identifier.endpage61en_US
dc.identifier.issn1304-3889
dc.identifier.issue2en_US
dc.identifier.scopus2-s2.0-41449099514en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.startpage57en_US
dc.identifier.urihttps://doi.org/10.29333/ejgm/82456
dc.identifier.urihttps://hdl.handle.net/20.500.12483/15240
dc.identifier.volume4en_US
dc.indekslendigikaynakScopusen_US
dc.language.isoenen_US
dc.publisherTIP ARASTIRMALARI DERNEGIen_US
dc.relation.ispartofEuropean Journal of General Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMyocardial infarctionen_US
dc.subjectThrombolytic therapyen_US
dc.subjectVon Willebrand factoren_US
dc.titleRelationship between von Willebrand factor activity and therapeutic success of thrombolytic therapy in patients with myocardial infarctionen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu